Page 80 - Read Online

Page 8 of 9 Gitto et al. Hepatoma Res 2020;6:22 I http://dx.doi.org/10.20517/2394-5079.2019.50

and host-targeting antiviral agents. J Infect 2014;68:1-20.
10. Sandmann L, Schulte B, Manns MP, Maasoumy B. Treatment of chronic hepatitis C: efficacy, side effects and complications. Visc Med
2019;35:161-70.
11. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-
related cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
12. Reig M, Mariño Z, Perelló C, Iñarrairaegui M, Ribeiro A, et al. Unexpected high rate of early tumor recurrence in patients with HCV-
related HCC undergoing interferon free therapy. J Hepatol 2016;65:719-26.
13. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic
patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol 2016;65:856-8.
14. Rinaldi L, Di Francia R, Coppola N, Guerrera B, Imparato M, et al. Hepatocellular carcinoma in HCV cirrhosis after viral clearance
with direct acting antiviral therapy: preliminary evidence and possible meanings. WCRJ 2016;3:e748.
15. Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular
carcinoma. J Hepatol 2017.
16. ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the
recurrence of hepatocellular carcinoma: data from three ANRS cohorts. J Hepatol 2016;65:734-40.
17. Ikeda K, Kawamura Y, Kobayashi M, Kominami Y, Fujiyama S, et al. Direct-acting antivirals decreased tumor recurrence after initial
treatment of hepatitis C virus-related hepatocellular carcinoma. Dig Dis Sci 2017;62:2932-42.
18. Grandhe S, Frenette CT. Occurrence and recurrence of hepatocellular carcinoma after successful direct-acting antiviral therapy for
patients with chronic hepatitis C virus infection. Gastroenterol Hepatol 2017;13:421-5.
19. Villani R, Facciorusso A, Bellanti F, Tamborra R, Piscazzi A, et al. DAAs rapidly reduce inflammation but increase serum VEGF
Level: a rationale for tumor risk during anti-HCV treatment. PLoS One 2016;11:e0167934.
20. El Kassas M, Funk AL, Salaheldin M, Shimakawa Y, Eltabbakh M, et al. Increased recurrence rates of hepatocellular carcinoma after
DAA therapy in a hepatitis C infected Egyptian cohort: a comparative analysis. J Viral Hepat 2018;25:623-30.
21. Saraiya N, Yopp AC, Rich NE, Odewole M, Parikh ND, et al. Systematic review with meta-analysis: recurrence of hepatocellular
carcinoma following direct acting antiviral therapy. Aliment Pharmacol Ther 2018;48:127-37.
22. Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, et al. Hepatocellular carcinoma risk following direct-acting antiviral HCV
therapy: a systematic review, metaanalyses, and meta-regression. J Hepatol 2017;67:1204-12.
23. Singh S, Nautiyal A, Loke YK. Oral direct-acting antivirals and the incidence or recurrence of hepatocellular carcinoma: a systematic
review and meta-analysis. Frontline Gastroenterol 2018;9:262-70.
24. Rutledge SM, Zheng H, Li DK, Chung RT. No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral
treatment: a meta-analysis. Hepatoma Res 2019;5:31.
25. Singal AG, Rich NE, Mehta N, Branch AD, Pillai A, et al. Direct-acting antiviral therapy for hepatitis C virus infection is associated
with increased survival in patients with a history of hepatocellular carcinoma. Gastroenterology 2019;157:1253-63.e2.
26. Van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, et al. Association between sustained virological response and all-cause
mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012;308:2584-93.
27. Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on
the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study. J Hepatol 2013;58:495-501.
28. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, et al. Eradication of hepatitis C virus infection and the development of
hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med 2013;158:329-37.
29. Faillaci F, Marzi L, Critelli R, Milosa F, Schepis F, et al. Liver angiopoietin-2 is a key predictor of de novo or recurrent hepatocellular
cancer after hepatitis C virus direct-acting antivirals. Hepatology 2018;68:1010-24.
30. Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, et al. Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular
carcinomas and worst survival. Results from a prospective study. Gut 2016;65:861-9.
31. Ravaioli F, Conti F, Brillanti S, Andreone P, Mazzella G, et al. Hepatocellular carcinoma risk assessment by the measurement of liver
stiffness variations in HCV cirrhotics treated with direct acting antivirals. Dig Liver Dis 2018;50:573-9.
32. Ioannou GN, Beste LA, Green PK, Singal AG, Tapper EB, et al. Increased risk for hepatocellular carcinoma persists up to 10 years
after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores. Gastroenterology 2019;157:1264-78.
33. El-Serag HB, Kanwal F. Obesity and hepatocellular carcinoma: hype and reality. Hepatology 2014;60:779-81.
34. El-Serag HB, Kanwal F, Richardson P, Kramer J. Risk of hepatocellular carcinoma after sustained virological response in Veterans
with hepatitis C virus infection. Hepatology 2016;64:130-7.
35. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and
hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014;60:98-105.
36. Kanwal F, White DL, Jiao L, Tavakoli-Tabasi S, Sansgiry S, et al. Genetic variants in interleukin-28B are associated with diabetes and
diabetes-related complications in patients with chronic hepatitis C virus infection. Dig Dis Sci 2015;60:2030-7.
37. Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, et al. Incidence of hepatocellular carcinoma after direct antiviral therapy for
HCV in patients with cirrhosis included in surveillance programs. Gastroenterology 2018;155:1436-50.
38. Ndrepepa G, Colleran R, Kastrati A. Gamma-glutamyl transferase and the risk of atherosclerosis and coronary heart disease. Clin
Chim Acta 2018;476:130-8.
39. Taliani G, Badolato MC, Nigro G, Biasin M, Boddi V, et al. Serum concentration of gammaGT is a surrogate marker of hepatic TNF-
alpha mRNA expression in chronic hepatitis C. Clin Immunol 2002;105:279-85.
40. Ghany MG, Morgan TR; AASLD-IDSA Hepatitis C Guidance Panel. Hepatitis C guidance 2019 update: american association for the
study of liver diseases-infectious diseases society of america recommendations for testing, managing, and treating hepatitis C virus
infection. Hepatology 2020;71:686-721.